Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults
- PMID: 18003811
- PMCID: PMC2238067
- DOI: 10.1128/CVI.00316-07
Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults
Abstract
The objective of this study was to evaluate and compare both the safety and tolerability and the humoral and cell-mediated immune responses for two influenza virus subunit vaccines, one with MF59 adjuvant (Fluad) and one without an adjuvant (Agrippal), in healthy and in human immunodeficiency virus type 1 (HIV-1)-infected adult individuals. To achieve this aim, an open, randomized, comparative clinical trial was performed during the 2005-2006 season. A total of 256 subjects were enrolled to receive one dose of vaccine intramuscularly. Blood samples were taken at the time of vaccination and at 1 and 3 months postvaccination. A good humoral antibody response was detected for both vaccines, meeting all the criteria of the Committee for Medical Products for Human Use. After Beyer's correction for prevaccination status, Fluad exhibited better immunogenicity than Agrippal, as shown from the analysis of the geometric mean titers, with significant differences for some virus strains; however, no definitive conclusions on the clinical significance of such results can be drawn, because the method used to estimate antibody response is currently nonstandard for influenza virus vaccines. Significant induction of an antigen-specific CD4+ T-lymphocyte proliferative response was detected at all time points after immunization, for both the vaccines, among HIV-1-seronegative subjects. This was different from what was observed for HIV-1-infected individuals. In this group, significance was not reached at 30 days postvaccination (T30) for those immunized with Agrippal. Also when data were compared between treatment groups, a clear difference in the response at T30 was observed in favor of Fluad (P = 0.0002). The safety profiles of both vaccines were excellent. For HIV-1-infected individuals, no significant changes either in viremia or in the CD4+ cell count were observed at any time point. The results showed good safety and immunogenicity for both vaccines under study for both uninfected and HIV-1-infected adults, confirming current recommendations for immunization of this high-risk category.
Figures
![FIG. 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2238067/bin/zcd0020831600001.gif)
Similar articles
-
Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.Hum Vaccin Immunother. 2015;11(3):553-63. doi: 10.1080/21645515.2015.1011562. Hum Vaccin Immunother. 2015. PMID: 25714138 Free PMC article. Review.
-
Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.Clin Vaccine Immunol. 2014 Jul;21(7):989-96. doi: 10.1128/CVI.00615-13. Epub 2014 May 14. Clin Vaccine Immunol. 2014. PMID: 24828092 Free PMC article. Clinical Trial.
-
Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.Hum Vaccin Immunother. 2012 Feb;8(2):216-27. doi: 10.4161/hv.18445. Epub 2012 Feb 1. Hum Vaccin Immunother. 2012. PMID: 22426371 Clinical Trial.
-
MF59 adjuvant: the best insurance against influenza strain diversity.Expert Rev Vaccines. 2011 Apr;10(4):447-62. doi: 10.1586/erv.11.23. Expert Rev Vaccines. 2011. PMID: 21506643 Review.
-
Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.J Prev Med Hyg. 2009 Jun;50(2):121-6. J Prev Med Hyg. 2009. PMID: 20099444
Cited by
-
Immunological and Clinical Responses to Vaccinations among Adults Living with HIV.Life (Basel). 2024 Apr 24;14(5):540. doi: 10.3390/life14050540. Life (Basel). 2024. PMID: 38792562 Free PMC article. Review.
-
Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocol.BMC Infect Dis. 2024 Mar 19;24(1):329. doi: 10.1186/s12879-024-09192-5. BMC Infect Dis. 2024. PMID: 38504173 Free PMC article. Clinical Trial.
-
A Biomimetic, Silaffin R5-Based Antigen Delivery Platform.Pharmaceutics. 2022 Dec 29;15(1):121. doi: 10.3390/pharmaceutics15010121. Pharmaceutics. 2022. PMID: 36678751 Free PMC article.
-
Serological Responses to Influenza Vaccination during Pregnancy.Microorganisms. 2021 Nov 6;9(11):2305. doi: 10.3390/microorganisms9112305. Microorganisms. 2021. PMID: 34835431 Free PMC article. Review.
-
Antibody Responsiveness to Influenza: What Drives It?Viruses. 2021 Jul 19;13(7):1400. doi: 10.3390/v13071400. Viruses. 2021. PMID: 34372607 Free PMC article. Review.
References
-
- Amendola, A., A. Boschini, D. Colzani, G. Anselmi, A. Oltolina, and R. Zucconi. 2001. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J. Med. Virol. 65:644-648. - PubMed
-
- Baldo, V., T. Baldovin, A. Floreani, A. M. Carraro, R. Trivello, and Family Medicine Group of Pianiga. 2007. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 25:3955-3961. - PubMed
-
- Baldo, V., T. Menegon, C. Bonello, A. Floreani, R. Trivello, and “Mariutto” Collaborative Group. 2001. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 19:3472-3475. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials